Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

Analyst Ratings

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (?)
Ratings Breakdown: 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $23.33 (5.01% upside)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Jefferies GroupReiterated RatingBuy$19.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015Stifel NicolausBoost Price TargetBuy$15.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2015SunTrust Banks Inc.Initiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2014 forward)

Earnings

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016$0.13N/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.06$0.10$0.08
Q2 20162$0.13$0.13$0.13
Q3 20162$0.19$0.23$0.21
Q4 20162$0.22$0.27$0.25
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateHeadline
07/30/16 09:23 AMIt's Earnings Time: What to Do with Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock - The Voice Registrar
07/27/16 07:04 PMCan Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Keep Up ... - Investor Newswire
07/26/16 12:01 PMETF’s with exposure to Supernus Pharmaceuticals, Inc. : July 26, 2016 -
07/26/16 10:04 AMNorthland Securities Downgrades Supernus Pharmaceuticals Inc to Market Perform - Trade Calls
07/23/16 10:25 AMBroker Outlook For Supernus Pharmaceuticals, Inc. (SUPN) - Fiscal Standard
07/23/16 10:25 AMOpaleye Management INC Decreased Stake in Supernus Pharmaceuticals INC (NASDAQ:SUPN) by $4.43 Million as ... - Press Telegraph
07/21/16 09:28 AMHow Many Supernus Pharmaceuticals Inc (NASDAQ:SUPN)'s Analysts Are Bearish? - Consumer Eagle
07/20/16 07:38 PMJuncture Wealth Strategies Lowers stake in Supernus Pharmaceuticals Inc (SUPN) - TheFounders Daily
07/20/16 03:36 PMSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
07/20/16 03:30 PMSupernus to Host Second Quarter 2016 Earnings Conference Call - [GlobeNewswire] - ROCKVILLE, Md., July 20, 2016-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
07/19/16 07:37 AMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 05:35 AMSupernus Pharma downgraded by Piper Jaffray and Northland Capital -
07/16/16 09:49 AMIncreased Volatility Noted on Shares of: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Engelwood Daily
07/15/16 11:53 AMCrowd Rating and Earnings Recap for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Telanagana Press
07/15/16 11:53 AMMurphy Michael R Decreased Stake in Supernus Pharmaceuticals INC (NASDAQ:SUPN) by $5.68 Million as Shares ... - Consumer Eagle
07/14/16 10:16 AMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 06:52 PMSupernus Pharmaceuticals Incorporated (NASDAQ:SUPN) Shorted Shares Decreased By 8.02% - Press Telegraph
07/12/16 10:59 AMTrading Performance and Target Watch for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Press Telegraph
07/12/16 10:59 AMShares Positive on the Year: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Telanagana Press
07/12/16 10:59 AMStock Moving Up This Week: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Telanagana Press
07/12/16 07:30 AMSupernus Pharmaceuticals Founder and CEO Jack Khattar joins scPharmaceuticals Board of Directors - [PR Newswire] - LEXINGTON, Mass., July 12, 2016 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Jack A. Khattar has been appointed to scPharmaceuticals' board of directors. Jack A. Khattar is the founder of Supernus Pharmaceuticals (SUPN) and has served as president and Chief Executive Officer and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions, including Board Member, president and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Prior to that, Mr. Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA, a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning.
07/11/16 06:34 PMIs Strong Growth Ahead for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Telanagana Press
07/11/16 10:14 AMStock on the Rise for the Quarter: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Engelwood Daily
07/11/16 10:14 AMStock Performance Rundown on: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Press Telegraph
07/09/16 09:39 AMMurphy Michael R Decreased Stake in Supernus Pharmaceuticals INC (NASDAQ:SUPN) by $5.68 Million as Shares ... - Press Telegraph
07/09/16 09:39 AMSupernus Pharmaceuticals Inc. (SUPN) is Trading Lower on Unusual Volume for July 07 - Equities.com
07/05/16 06:17 PMShares With YTD Gains: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Telanagana Press
07/05/16 06:17 PMSupernus Pharmaceuticals, Inc. (SUPN) Broker Price Targets For The Coming Week - Fiscal Standard
07/03/16 05:51 PMShare Performance Recap for: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Press Telegraph
07/03/16 09:48 AMSupernus Pharmaceuticals Incorporated (NASDAQ:SUPN) Sellers Covered 8.02% of Their Shorts - Engelwood Daily
06/30/16 03:25 PMShare Update and Earnings Review for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Press Telegraph
06/30/16 03:25 PMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Company Rating and Target Watch - Telanagana Press
06/30/16 09:30 AM4 health stocks to watch -
06/29/16 09:22 AM4 Stocks To Watch: ANIP, NVAC, SUPN, TDOC
06/27/16 06:33 PMSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Earnings Glance and Target Price Review - Engelwood Daily
06/27/16 09:59 AMTake a look at Analysts Tips: Tenet Healthcare Corporation (NYSE:THC) , Supernus Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
06/27/16 09:59 AMNext Weeks Broker Price Targets For Supernus Pharmaceuticals, Inc. (SUPN) - Fiscal Standard
06/24/16 09:11 AMRecently Issued Stock Ratings For Supernus Pharmaceuticals, Inc. (SUPN) - Fiscal Standard
06/22/16 06:34 PMSupernus Pharmaceuticals, Inc. (NasdaqGM:SUPN) Stock Momentum Hits Strength - CML News
06/22/16 06:34 PMSupernus Pharmaceuticals Inc. (SUPN) is Trading Higher on Unusual Volume for June 20 - Equities.com
06/22/16 06:34 PMSupernus Pharma (SUPN) Issued Seventh U.S. Patent Related to Oxtellar XR - StreetInsider.com
06/22/16 03:30 PM4:30 pm Supernus Pharma announces the issuance of a seventh patent covering Oxtellar XR -
06/22/16 03:30 PMSupernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR® - [GlobeNewswire] - ROCKVILLE, Md., June 22, 2016-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
06/20/16 08:07 AMSupernus Pharmaceuticals, Inc. (SUPN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 06:20 PMCAPR Vaults On Study, CRBP Awaits Data In Q4, OASIS A Shot In The Arm For PRTK
06/17/16 06:20 PMSupernus Pharmaceuticals : Pharma (SUPN) Still in Talks with FDA Over Trokendi XR sNDA; Reaffirms Outlook
06/17/16 09:18 AMSupernus Pharma (SUPN) Still in Talks with FDA Over Trokendi XR sNDA; Reaffirms Outlook
06/16/16 06:50 PMSupernus Pharma (SUPN) Still in Talks with FDA Over Trokendi XR sNDA; Reaffirms Outlook - StreetInsider.com
06/16/16 03:49 PMSupernus Provides Update on Trokendi XR® Migraine sNDA and Reiterates Guidance - [at noodls] - June 16, 2016 ROCKVILLE, Md., June 16, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the ...
06/09/16 12:30 PMETF’s with exposure to Supernus Pharmaceuticals, Inc. : June 9, 2016 -

Social

About Supernus Pharmaceuticals

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SUPN
  • CUSIP: 86845910
Key Metrics:
  • Previous Close: $22.22
  • 50 Day Moving Average: $20.26
  • 200 Day Moving Average: $16.43
  • P/E Ratio: 65.74
  • P/E Growth: 0.47
  • Market Cap: $1.10B
  • Beta: 1.75
  • Current Year EPS Consensus Estimate: $0.64 EPS
  • Next Year EPS Consensus Estimate: $1.39 EPS
Additional Links:
Supernus Pharmaceuticals (NASDAQ:SUPN) Chart for Sunday, July, 31, 2016